Influence of Pentraxin 3 (PTX3) Genetic Variants on Myocardial Infarction Risk and PTX3 Plasma Levels

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Barbati, Elisa ^a,b   Specchia, Claudia ^c,d   Villella, Massimo ^e   Rossi, Marco Luciano ^a   Barlera, Simona ^c   Bottazzi, Barbara ^a   Crociati, Luisa ^c   d'Arienzo, Carmela ^e   Fanelli, Raffaele ^e   Garlanda, Cecilia ^a   Gori, Francesca ^c   Mango, Ruggiero ^a   Mantovani, Alberto ^a,b   Merla, Giuseppe ^e   Nicolis, Enrico B ^c   Pietri, Silvia ^c   Presbitero, Patrizia ^a   Sudo, Yukio ^f   Villella, Alessandro ^g   Franzosi, Maria Grazia ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f Perseus Proteomics   (Japan)

^g F Lastaria Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HAPLOTYPE MAP; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSMOLAR CONCENTRATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SERUM AMYLOID P-COMPONENT;

EID: 84871672282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053030     Document Type: Article

References (39)

1. Dahlof B, (2010) Cardiovascular disease risk factors: epidemiology and risk assessment. The American Journal of Cardiology 105: 3A-9A.
2. Lloyd-Jones DM, (2010) Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 121: 1768-1777.
3. Hansson GK, Hermansson A, (2011) The immune system in atherosclerosis. Nature immunology 12: 204-212.
4. Hansson GK, (2005) Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 352: 1685-1695.
5. Arroyo-Espliguero R, Avanzas P, Jeffery S, Kaski JC, (2004) CD14 and toll-like receptor 4: a link between infection and acute coronary events? Heart 90: 983-988.
6. Pasterkamp G, Van Keulen JK, De Kleijn DP, (2004) Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. European Journal of Clinical Investigation 34: 328-334.
7. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB, (2008) C-reactive protein and coronary heart disease: a critical review. Journal of Internal Medicine 264: 295-314.
8. Garlanda C, Bottazzi B, Bastone A, Mantovani A, (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annual review of Immunology 23: 337-366.
9. Norata GD, Garlanda C, Catapano AL, (2010) The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends in Cardiovascular Medicine 20: 35-40.
10. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, et al. (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arteriosclerosis, Thrombosis, and Vascular Biology 22: e10-14.
11. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, et al. (2008) Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. The Journal of Pathology 215: 48-55.
12. Bottazzi B, Doni A, Garlanda C, Mantovani A, (2010) An integrated view of humoral innate immunity: pentraxins as a paradigm. Annual review of Immunology 28: 157-183.
13. Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, et al. (2010) Regulation of leukocyte recruitment by the long pentraxin PTX3. Nature Immunology 11: 328-334.
14. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, et al. (2002) Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420: 182-186.
15. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, et al. (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 161-167.
16. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, et al. (2008) Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197: 368-374.
17. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, et al. (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. American Heart Journal 155: 75-81.
18. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, et al. (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102: 636-641.
19. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, et al. (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354.
20. Salio M, Chimenti S, De Angelis N, Molla F, Maina V, et al. (2008) Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 117: 1055-1064.
21. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, et al. (2009) Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708.
22. Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, et al. (2007) DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes and immunity 8: 456-467.
23. Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, et al. (2010) PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes and Immunity 11: 665-670.
24. May L, Kuningas M, van Bodegom D, Meij HJ, Frolich M, et al. (2010) Genetic variation in pentraxin (PTX) 3 gene associates with PTX3 production and fertility in women. Biology of Reproduction 82: 299-304.
25. GISSI Prevenzione Investigators, (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354: 447-455.
26. Miller SA, Dykes DD, Polesky HF, (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 16: 1215.
27. Gauderman WJ, Morrison JM (2006) QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. Available: http://hydra.usc.edu/gxe. Accessed 2012 July 19.
28. Dudbridge F, (2008) Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Human Heredity 66: 87-98.
29. Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, et al. (2008) Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. The Journal of Biological Chemistry 283: 10147-10161.
30. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, et al. (2012) Variation in PTX3 Is Associated with Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine 186: 546-552.
31. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM, (2009) Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 594-599.
32. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, et al. (2010) Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 210: 220-225.
33. Chang MK, Binder CJ, Torzewski M, Witztum JL, (2002) C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proceedings of the National Academy of Sciences of the United States of America 99: 13043-13048.
34. Zhang YX, Cliff WJ, Schoefl GI, Higgins G, (1999) Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 145: 375-379.
35. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375: 132-140.
36. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England Journal of Medicine 350: 1387-1397.
37. Verzilli C, Shah T, Casas JP, Chapman J, Sandhu M, et al. (2008) Bayesian meta-analysis of genetic association studies with different sets of markers. American Journal of Human Genetics 82: 859-872.
38. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, et al. (2008) Genetically elevated C-reactive protein and ischemic vascular disease. The New England Journal of Medicine 359: 1897-1908.
39. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, et al. (2011) Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. British Medical Journal 342: d548.